Johnson and Johnson Beat Q1 Estimates and Raised Its Full-Year Revenue Outlook Toward $101 Billion

J&J doesn't usually make noise on earnings day. The firm is steady. It's boring. It rarely shocks anyone. On Tuesday, it shocked. J&J put up first-quarter sales of $24.1 billion. That's nearly 10% more than a year ago and above the $23.6 billion that Wall Street called for. Earnings came in at $2.70 per share, beating the $2.68 guess. The stock moved higher. And the company raised its outlook for the year.

Two Drugs Are Doing Most of the Work

Cancer drug Darzalex and skin treatment Tremfya both posted strong sales in the quarter. Together, they more than made up for a big drop in revenue from Stelara. That's J&J's best-selling immune drug, and it now faces copycats that are cheaper. The guidance raise matters. J&J bumped its full-year sales call to about $100.8 billion. That's just above the $100.6 billion Wall Street had penciled in. It may sound small. But J&J has a habit of starting the year with a low target and raising it later. This is the first raise, and more could come. What $100 billion means: If J&J hits that mark, it would be one of the few health care firms to ever cross $100 billion in sales in a single year. That's a huge number for a company that most people think of as the maker of Band-Aids and baby shampoo.

The Dividend Keeps Growing

J&J raised its quarterly payout by 3.1% to $1.34 per share. That puts the full-year check at $5.36. The firm has raised its payout for more than 60 years in a row. That's one of the longest streaks of any stock in the market. For income investors, this is the dream quarter. A beat on earnings. A raise in the outlook. And a bigger check landing in your account every 90 days. Why income investors love J&J: In a market full of wild swings and war-driven chaos, a stock that pays you more every year feels like a safe harbor. J&J isn't going to double overnight. But it's also not going to blow up.

The Pipeline Ahead

J&J has more than 100 drugs in its pipeline right now. Many are in late-stage trials. The firm is betting big on cancer, immune diseases, and lung health. If even a few of those pan out, the growth runway gets much longer. The company is also leaning into med-tech - devices and tools used in surgery. That side of the business grew 4% in Q1 and could become a bigger part of the profit mix over time.

What to Watch

J&J got lost in the noise on Tuesday. Bank earnings from JPMorgan and Citi stole the show. But for investors who care about steady growth and rising payouts, this was one of the best reports of the day. Watch next quarter for signs that the pipeline is starting to pay off.

The Stelara Risk

There is one cloud hanging over J&J. Stelara brought in more than $10 billion a year at its peak. Now that generic copies are on the market, sales are falling fast. The company needs its newer drugs to fill that gap. Darzalex and Tremfya are doing it so far. But the next two years will show if the rest of the pipeline can keep the growth going once Stelara fades further.